FDA advisors to review Combidex in March
This article was originally published in Clinica
Executive Summary
A US FDA advisory panel is to review on March 3, Advanced Magnetics' MRI-guided imaging agent, Combidex. Following a review from the agency's Oncologic Drugs Advisory Committee (ODAC), an action date with the FDA is scheduled for March 30.